New FDA-approved and investigational therapies target apoC-III to reduce triglycerides in familial chylomicronemia syndrome. Can you identify how these agents work?
New FDA-approved and investigational therapies target apoC-III to reduce triglycerides in familial chylomicronemia syndrome. Can you identify how these agents work?
New FDA-approved and investigational therapies target apoC-III to reduce triglycerides in familial chylomicronemia syndrome. Can you identify how these agents work?
A new study found transcranial pulse stimulation treatment may improve behavioral symptoms such as aggression or agitation in patients with Alzheimer disease. Take our quiz to test your knowledge on its...
A new study found transcranial pulse stimulation treatment may improve behavioral symptoms such as aggression or agitation in patients with Alzheimer disease. Take our quiz to test your knowledge on its...
A new study found transcranial pulse stimulation treatment may improve behavioral symptoms such as aggression or agitation in patients with Alzheimer disease. Take our quiz to test your knowledge on its...
A recent review highlights key genetic abnormalities in chronic lymphocytic leukemia which predict faster disease progression and treatment resistance. Test your knowledge!
A recent review highlights key genetic abnormalities in chronic lymphocytic leukemia which predict faster disease progression and treatment resistance. Test your knowledge!
A recent review highlights key genetic abnormalities in chronic lymphocytic leukemia which predict faster disease progression and treatment resistance. Test your knowledge!
A recent review highlights key genetic abnormalities in chronic lymphocytic leukemia which predict faster disease progression and treatment resistance. Test your knowledge!
